At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Rodríguez-Otero is medical coordinator of the Central Unit for Clinical Trials; associate clinical professor, preclinical and ...

Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, ...

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

Supportive care, including intravenous immunoglobulin, may improve outcomes by reducing infection risk in patients treated ...

Legend Biotech Corp's stock is navigating a period of significant market turbulence. A downward trend has persisted for the ...